Clinical Trial

HQP1351CU101: A Phase 1b Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects with Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)

This research study is being done to test an investigational drug called HQP1351 (the study drug). Investigational means the study drug being tested has not been approved by the United States Food and Drug Administration (FDA). You are being invited to take part in this research study because you have Chronic Myeloid Leukemia (CML) or Philadephia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) and have been treated with 3 of the approved drugs to treat your disease, but your treatment has been discontinued because these drugs are no longer effective or you could not tolerate the side effects. We are doing this research study to find the best dose of the study drug to use for future research studies.

• Circulatory System
• Cancer
• Chronic Myeloid Leukemia
• CML
• Hematologic Malignancies
• Ph+ALL
• Philadephia Chromosome-positive Acute Lymphoblastic Leukemia